{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-000908","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.210641+00:00","generated_at":"2026-06-20T18:16:44.528868+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Biofrontera reports preliminary Q4 2022 revenue of ~$10.2-10.4M, up 12% YoY; FY2022 record $28.7-28.9M","bullets":["Preliminary Q4 2022 revenue $10.2-10.4M, an increase of approximately 12% vs Q4 2021.","Full year 2022 revenue of $28.7-28.9M, a record high and up ~20% compared to 2021.","CEO Erica Monaco cites continued expansion of Ameluz-PDT for actinic keratosis as driver.","Final Q4 and FY2022 financial results expected in March 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-000908","json":"https://secwatch.observer/filing/0001493152-23-000908.json","markdown":"https://secwatch.observer/filing/0001493152-23-000908.md","text":"https://secwatch.observer/filing/0001493152-23-000908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223000908/0001493152-23-000908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223000908/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:16:44.528868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c6451c7513d6d5f61fd9dbea14fdc938660ac446","claim":"Biofrontera Inc. reported fourth quarter and year ended December 31, 2022 results: revenue $10.2 million to $10.4 million.","evidence_excerpt":"Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenues for the three and 12 months ended December 31, 2022. Revenues for the fourth quarter of 2022 are anticipated to be in the range of approximately $10.2 million to $10.4 million, an increase of approximately 12% compared with the fourth quarter of 2021. These projections result in 2022 revenue of approximately $28.7 million to $28.9 million, a record high and up approximately 20% compared with 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223000908/0001493152-23-000908-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$10.2 million to $10.4 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}